Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiology Could Get A Jolt As FDA Reviews Novel Heart Failure Candidates From BMS, Cytokinetics

Executive Summary

Upcoming US FDA decisions could bring breakthrough-designated approvals for BI/Lilly’s Jardiance in heart failure with preserved ejection fraction and BMS’ mavacamten in hypertrophic cardiomyopathy, while Cytokinetics bids to bring a new mechanism the busy heart failure with reduced ejection fraction space and earns a BTD in HCM.

You may also be interested in...



Keeping Track: Mycovia Vivjoa, BMS Camzyos Approvals Bring FDA’s 2022 Novel Drug Tally To 12

US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.

Keeping Track: US FDA Approves Carvykti, Vonjo, But Turns Down Lenacapavir, Filsuvez And GC1507

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track: Jardiance Approved Across Heart Failure Spectrum, But US FDA Turns Down Bardoxolone, Terlipressin

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel